Amgen Inc. (FRA:AMG)
Germany · Delayed Price · Currency is EUR | Market Cap | 150.96B |
| Revenue (ttm) | 30.66B |
| Net Income (ttm) | 5.97B |
| Shares Out | n/a |
| EPS (ttm) | 11.02 |
| PE Ratio | 25.29 |
| Forward PE | 15.65 |
| Dividend | 8.52 (3.01%) |
| Ex-Dividend Date | Nov 21, 2025 |
| Volume | 90 |
| Average Volume | 123 |
| Open | 282.95 |
| Previous Close | 287.85 |
| Day's Range | 282.75 - 285.90 |
| 52-Week Range | 230.00 - 304.75 |
| Beta | n/a |
| RSI | 52.00 |
| Earnings Date | Feb 3, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial numbers in USD Financial StatementsNews
Amgen Reaches Analyst Target Price
In recent trading, shares of Amgen Inc (Symbol: AMGN) have crossed above the average analyst 12-month target price of $330.74, changing hands for $341.64/share. When a stock reaches the target an anal...
AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., Jan. 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2026 J.P.
Notable Wednesday Option Activity: ASTS, STZ, AMGN
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AST SpaceMobile Inc (Symbol: ASTS), where a total volume of 135,862 contracts has ...
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs
Amgen acquires Dark Blue Therapeutics for up ... Full story available on Benzinga.com
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs
On Tuesday, Amgen Inc. (NASDAQ: AMGN) acquired Dark Blue Therapeutics, a discovery and development biotech company focused on precision oncology medicines.
Stocks making the biggest moves midday: Deckers Outdoor, Amgen, Western Digital, Ventyx Biosciences & more
Check out some of the biggest movers in midday trading.
Dow Movers: JPM, AMGN
In early trading on Wednesday, shares of Amgen topped the list of the day's best performing Dow Jones Industrial Average components, trading up 2.6%. Year to date, Amgen registers a 3.5% gain. And the...
UBS Raises Amgen (AMGN) Price Target to $380 and Upgrades to Buy | AMGN Stock News
UBS Raises Amgen (AMGN) Price Target to $380 and Upgrades to Buy | AMGN Stock News
Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline
AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.
UBS Upgrades Amgen (AMGN) to Buy, Raises Price Target to $380
UBS Upgrades Amgen (AMGN) to Buy, Raises Price Target to $380
Amgen upgraded to buy at UBS on potential of MariTide, olpasiran
Amgen Agrees to Buy Dark Blue Therapeutics in Up to $840 Million Deal
Amgen Agrees to Buy Dark Blue Therapeutics in Up to $840 Million Deal
Amgen (AMGN) Acquires Dark Blue Therapeutics for $840 Million
Amgen (AMGN) Acquires Dark Blue Therapeutics for $840 Million
Amgen (AMGN) Expands Oncology Portfolio with Acquisition of Dark Blue Therapeutics
Amgen (AMGN) Expands Oncology Portfolio with Acquisition of Dark Blue Therapeutics
Amgen Acquires Privately-held Dark Blue Therapeutics In $840 Mln Deal
(RTTNews) - Amgen, Inc. (AMGN) announced Tuesday its acquisition of UK-based privately-held biotechnology company Dark Blue Therapeutics Ltd. in a transaction valued at up to $840 million.
Amgen acquires Dark Blue Therapeutics for up to $840 million
Amgen (AMGN) acquires Dark Blue Therapeutics for up to $840M, adding AML-focused protein degrader oncology pipeline.
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced its acquisiti...
Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Amgen (AMGN) stood at $320.71, denoting a -2.12% move from the preceding trading day.
Beat the Market the Zacks Way: LATAM, General Motors, Amgen in Focus
LTM, GM and AMGN highlight Zacks' recent stock-picking wins, delivering notable gains across airlines, autos and biotech despite choppy markets.
Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites
The Dow Jones Industrial Average hit record all-time highs in 2025 with many of the components ending the year higher. Along with serving as a well-known barometer of overall market health, the index ...
Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites
The Dow Jones Industrial Average hit record all-time highs in 2025 with many of the components ending the year higher. Along with serving as a well-known barometer of overall market health, the index ...
XLV, ABT, AMGN, GILD: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street Health Care Select Sector SPDR ETF (Symbol: XLV) where we...
How To YieldBoost Amgen To 5.5% Using Options
Shareholders of Amgen Inc (Symbol: AMGN) looking to boost their income beyond the stock's 3.1% annualized dividend yield can sell the January 2028 covered call at the $420 strike and collect the premi...
These three ‘Dogs of the Dow' stocks are must-own for 2026
The “Dogs of the Dow” strategy has staged a comeback, and Kevin Simpson of Capital Wealth Planning believes 2026 could be another strong year. After a 17% gain in 2025, beating the broader Dow's perfo...
BMY vs AMGN: Which Biotech Stock Is More Resilient Now?
AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.